Completed PHASE2 INTERVENTIONAL 2-arm NCT01627262

Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study

Double-blind, Randomised, Placebo-controlled, Parallel-group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Pellets vs. Placebo in Diverticular Disease

Sponsor: Dr. Falk Pharma GmbH

Conditions Colonic Diverticulosis

Interventions Mesalamine Placebo

Updated 6 times since 2017 Last updated: Jan 20, 2016 Started: May 31, 2002 Primary completion: Aug 31, 2004 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01627262, this PHASE2 trial focuses on Colonic Diverticulosis and remains completed. Sponsored by Dr. Falk Pharma GmbH, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Falk Pharma GmbH

Data source: Dr. Falk Pharma GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cologne, Germany